Search Results - "Seront, E."

Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic review by Pierrard, J, Seront, E

“…Immune checkpoint inhibitors (icis) are increasingly being used in clinical practice, improving outcomes for cancer patients. Preclinical models showed…”
Get full text

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation by Seront, E, Pinto, A, Bouzin, C, Bertrand, L, Machiels, J-P, Feron, O

“…Background: Preclinical studies have shown that PTEN loss enhances sensitivity to mammalian target of Rapamycin (mTOR) inhibitors because of facilitated PI3K…”
Get full text

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study by van Marcke, C, Honoré, N, van der Elst, A, Beyaert, S, Derouane, F, Dumont, C, Aboubakar Nana, F, Baurain, J F, Borbath, I, Collard, P, Cornélis, F, De Cuyper, A, Duhoux, F P, Filleul, B, Galot, R, Gizzi, M, Mazzeo, F, Pieters, T, Seront, E, Sinapi, I, Van den Eynde, M, Whenham, N, Yombi, J C, Scohy, A, van Maanen, A, Machiels, J P

“…The viral pandemic coronavirus disease 2019 (COVID-19) has disrupted cancer patient management around the world. Most reported data relate to incidence, risk…”
Get full text

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers by Seront, E., Rottey, S., Sautois, B., Kerger, J., D'Hondt, L.A., Verschaeve, V., Canon, J.-L., Dopchie, C., Vandenbulcke, J.M., Whenham, N., Goeminne, J.C., Clausse, M., Verhoeven, D., Glorieux, P., Branders, S., Dupont, P., Schoonjans, J., Feron, O., Machiels, J.-P.

“…This phase II study assessed the safety and efficacy of everolimus, an oral mammalian target of rapamycin inhibitor in advanced transitional carcinoma cell…”
Get full text

Clinical, biological and histological features predictive of response to everolimus in metastatic breast cancer patients by Van den bossche, V., Jadot, G., Augusto, D., Samartzi, V., Castela, S., Lejeune, S., Seront, E.

Get full text

A guided and personalised treatment in metastatic breast cancer: Optimisation of gene and protein expression in tumor tissue by Seront, E., Lejeune, S., Petit, B., Samartzy, V., Sauvage, S., Laes, J.-F.

Get full text

Palmar fasciitis and polyarthritis, a rare paraneoplastic syndrome related to ovarian cancer by Marcke, C., Seront, E., Docquier, C., Filleul, B.

“…Summary Palmar fasciitis and polyarthritis syndrome (PFPAS) is an uncommon disorder characterized by diffuse inflammation of the palmar fascia, tendon sheaths,…”
Get full text

Retrospective analysis of definitive chemoradiotherapy with either high-dose or weekly cisplatin in patients with locally advanced squamous cell head and neck cancer: 2-year outcome by Van Marcke, C, Petit, B, Confente, C, Filleul, B, Neybuch, Y, Christian, N, Rosier, J.F, Mitine, C, Seront, E

Get full text

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours by Seront, E, Boidot, R, Bouzin, C, Karroum, O, Jordan, B F, Gallez, B, Machiels, J-P, Feron, O

“…Background: Hypoxia can activate autophagy, a self-digest adaptive process that maintains cell turnover. Mammalian target of rapamycin (mTOR) inhibitors are…”
Get full text

Impact of Non-Steroidal Anti-inflammatory Drugs (NSAIDs) use on the efficacy and safety of immune Checkpoint Inhibitors (CPI) in patients with advanced Renal Cell Carcinoma (RCC) and Urothelial Carcinoma (UC): A retrospective multicenter analysis by Martinez Chanza, N., Gizzi, M., Van Damme, J., Trevesi, E., Seront, E.

Get full text

2858 Definitive chemoradiotherapy with either high-dose or weekly cisplatin in patients with locally advanced squamous cell head and neck cancer: A retrospective analysis by van Marcke, C, Petit, B, Confente, C, Filleul, B, Neybuch, Y, Christian, N, Rosier, J.F, Mitine, C, Seront, E

Get full text

Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future by Geukens, T., Brandão, M., Laenen, A., Collignon, J., Van Marcke, C., Louviaux, I., Demey, W., Van Wambeke, S., Schrijvers, D., Lecomte, S., Mebis, J., Rutten, A., Fontaine, C., Lybaert, W., Aspeslagh, S., Goeminne, J.-C., Van Den Bulck, H., Seront, E., De Backer, L., De Roock, W., Ignatiadis, M., Prenen, H., Van Beckhoven, D., Heijlen, M., Verheezen, J., Rottey, S., Punie, K., de Azambuja, E.

“…Solid cancer is an independent prognostic factor for poor outcome with COVID-19. As guidelines for patient management in that setting depend on retrospective…”
Get full text

Liver-Directed Therapies: Does It Make Sense in the Current Therapeutic Strategy for Patients With Confined Liver Colorectal Metastases? by Seront, E, Van den Eynde, M

“…Abstract Nearly half of patients with colorectal cancer will have metastases in the course of their disease and the liver appears to be the most common…”
Get full text

PP 72 Angiogenesis-related cytokines as potential predictive biomarkers in a phase II trial evaluating everolimus efficacy in locally advanced or metastatic Transitional Carcinoma Cell by Seront, E, Rottey, S, Sautois, B, D'Hondt, L, Canon, J-L, Vandenbulcke, J-M, Whenham, N, Goeminne, J-C, Feron, O, Machiels, J-P

Get full text

NEW DRUGS IN MEDICAL ONCOLOGY: NEW DIFFICULTIES TO DISTINGUISH DRUG-INDUCED SIDE EFFECTS FROM CANCER COMPLICATIONS: A CASE-REPORT by SERONT, E, MAZZEO, F, MANO, M, STERCKX, M, HUMBLET, Y, MACHIELS, J. P, BAURAIN, J. F

“…We report the case of a woman with a metastatic breast cancer, who started a third-line treatment with dasatinib, a new oral tyrosine kinase inhibitor, and who…”
Get full text

About two intra-aortic masses by Seront, E, de Saint-Hubert, G, Gilbeau, J.P, Van Ruyssevelt, P, Derue, G

Get full text

111P Evaluating the protective effect of metformine on cancer: A retrospective cohort analysis by Honoré, N., Van Der Elst, A., D'Augusto, D., Seront, E.

Get full text

PO-1466 PFS Following SBRT for Visceral Oligometastatic Prostate Cancer: A Multicenter Retrospective Study by Rogé, M., Franzese, C., Scorsetti, M., Khalifa, J., Pasquier, C., Blanchard, P., Terlizzi, M., Seront, E., Supiot, S.

Get full text

A0839 - Papillary Renal Cell Carcinoma (pRCC): Outcomes of patients receiving first-line immune-based combinations or Tyrosine Kinase Inhibitors (TKIs) from the ARON-1 study by Mollica, V., Massari, F., Fiala, O., Kucharz, J., Molina-Cerrillo, J., Seront, E., Bourlon, M.T., Pichler, R., Myint, Z.W., Kanesvaran, R., Marchetti, A., Rosellini, M., Rescigno, P., de Liano, A.G., Zakopoulou, R., Buti, S., Porta, C., Grande, E., Santoni, M.

Get full text

Papillary Renal Cell Carcinoma (pRCC): Outcomes of patients receiving first-line immune-based combinations or Tyrosine Kinase Inhibitors (TKIs) from the ARON-1 study by Mollica, V., Massari, F., Fiala, O., Kucharz, J., Molina-Cerrillo, J., Seront, E., Bourlon, M.T., Pichler, R., Myint, Z.W., Kanesvaran, R., Marchetti, A., Rosellini, M., Rescigno, P., de Liano, A.G., Zakopoulou, R., Buti, S., Porta, C., Grande, E., Santoni, M.

Get full text